The Global Antiserum Market was valued at USD 2.1 Billion in 2024 and is projected to reach USD 2.7 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period (2024-2028). This expansion is driven by increasing zoonotic disease prevalence, government immunization programs, and rising demand for emergency therapeutics in developing nations.
As global health organizations prioritize rapid-response biologics for infectious diseases and envenomation cases, pharmaceutical leaders are innovating production processes and expanding distribution networks. Here we examine the Top 10 Companies in the Antiserum Industry – plasma specialists, vaccine giants, and research pioneers delivering critical antibody therapies.
🔟 1. CSL Behring
Headquarters: King of Prussia, Pennsylvania, USA
Key Offering: Hyperimmune globulins, antivenoms, immunoglobulin therapies
CSL Behring dominates the plasma protein therapeutics market with 16.3% global market share. The company’s integrated approach from plasma collection to fractionation ensures reliable antiserum supplies for hospitals worldwide.
Strategic Developments:
- Current plasma collection capacity: 18 million liters annually
- 2023 acquisition of Vifor Pharma expanded critical care portfolio
- Pioneering recombinant antivenom technology with 30% faster production
Download FREE Sample Report: Antiserum Market – View in Detailed Research Report
9️⃣ 2. Grifols, S.A.
Headquarters: Barcelona, Spain
Key Offering: Plasma-derived immunoglobulins, specialty antivenoms
Grifols operates the world’s largest plasma collection network, processing over 9 million liters annually. The company’s proprietary fractionation technology achieves 92% protein recovery rates.
Strategic Developments:
- $2.1 billion invested in North American plasma facilities (2022-2024)
- New lyophilized antivenom formulation extends shelf life by 18 months
8️⃣ 3. Bharat Serums and Vaccines Limited
Headquarters: Mumbai, India
Key Offering: Snake antivenoms, rabies immunoglobulin
BSV supplies 42% of India’s antivenom demand with products effective against all major venomous species. The company’s heat-stable formulations are crucial for tropical climates.
Strategic Developments:
- WHO-prequalified antivenom priced 60% below competitors
- New African distribution hub opened in Nairobi (2023)
7️⃣ 4. Pfizer Inc.
Headquarters: New York, USA
Key Offering: Specialty immunoglobulins, antitoxins
Pfizer’s hospital biotherapeutics division leverages mRNA technology to develop next-generation antisera with improved efficacy profiles.
Strategic Developments:
https://shorturl.fm/oYjg5